PHOENIX, Aug. 3, 2016 /Weed Wire/ — Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced financial results for the three-month period ended June 30, 2016.
Tag Archives: INSY
PHOENIX, May 24, 2016 /Weed Wire/ — Insys Therapeutics, Inc. (NASDAQ: INSY) (“Insys” or “the Company”) today announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy.
Investors may be lulled into thinking that stocks they own or study in the cannabis space are insulated from what’s happening in the broader market. But that’s simply not true, and violates one of the oldest maxims in investing: Don’t fight the tape.
Last Wednesday, two pain specialists that were top subscribers of Insys Therapeutics’ (NASDAQ: INSY) leading prescription therapy Subsys were arrested, as part of a year-long operation by the DEA.
In the past few weeks we have seen some massive volatility in the most active cannabis stocks. At the same time we have seen broad market indexes like the NASDAQ and the S&P 500 hit new record highs, begging the question of whether the cannabis stocks are just following general momentum.
The early leaders in market cap (the total value of publicly-traded equity) in a expanding industry like cannabis can tell us a lot. These companies have a lot of advantages by being on this perch, but also some responsibilities.
Marijuana stocks come in two flavors. Companies using marijuana to derive compounds that can be turned into FDA-approved drugs to treat specific diseases — GW Pharmaceuticals (NASDAQ: GWPH) and Insys (NASDAQ: INSY).
CORAL SPRINGS, Florida, October 7, 2014 /PRNewswire/ –Biotech and Pharmaceutical companies focus on the development and commercialization of therapeutics for patients with infectious diseases as well as forecasts project legal medical marijuana.